JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Mucus production and chronic obstructive pulmonary disease, a possible treatment target: zooming in on N-acetylcysteine

  • 0Section of Respiratory Medicine, Department of Translational Medicine, University of Ferrara.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace +

|

January 15, 2025

|

January 15, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

N-acetylcysteine (NAC) can improve mucus properties and reduce inflammation in chronic obstructive pulmonary disease (COPD). Early NAC treatment may help prevent COPD development by addressing mucus dysfunction.

Area Of Science

  • Pulmonary Medicine
  • Pharmacology

Background

  • Mucus hypersecretion is a key feature of Chronic Obstructive Pulmonary Disease (COPD), linked to worse patient outcomes.
  • Mucus dysfunction may precede airway obstruction, suggesting a potential for early intervention and prevention.

Purpose Of The Study

  • To review the role of mucus dysfunction in COPD pathophysiology.
  • To explore the rationale for using N-acetylcysteine (NAC) in managing COPD-related mucus issues.

Main Methods

  • This study is a narrative literature review.
  • It examines the mechanisms of action for N-acetylcysteine (NAC) in relation to mucus properties and inflammation.

Main Results

  • N-acetylcysteine (NAC) modifies mucus rheology, enhancing clearance and reducing MUC5AC expression.
  • NAC exhibits antioxidant effects via direct action and glutathione replenishment.
  • NAC inhibits inflammatory pathways, including NF-kB activation and reduces pro-inflammatory cytokines like TNF-α, IL-6, and IL-10.

Conclusions

  • N-acetylcysteine (NAC) demonstrates potential therapeutic benefits for COPD by improving mucus clearance and reducing inflammation.
  • NAC may be a viable candidate for early treatment in individuals at risk of developing COPD.

Related Concept Videos

Cystic Fibrosis: Management 01:24

139

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Drugs Used in Upper Respiratory Disorders: Overview 01:16

177

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics 01:23

230

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...

Chronic Obstructive Pulmonary Disease-II: Pathophysiology 01:20

2.7K

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

• Inhalation of Irritants: Inhaling irritants, especially cigarette smoke, are primary causes of inflammation in COPD. Other irritants can include...

COPD: Management Using Bronchodilators and Corticosteroids 01:26

177

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Acute Respiratory Failure-V 01:29

123

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...